Home » Topics » BioWorld Science

BioWorld Science
RSS

Immune Response in-licenses gene therapy for brain tumors

April 12, 1996

NT-3 lessens cisplatin toxicity in rats

April 12, 1996

Thalidomide in phase II at NCI for cancer indications

April 12, 1996

Banyu reports synthesis and activity of BE-39907A2

April 12, 1996

Banyu discovers new thioredoxin system inhibitor

April 12, 1996

Isis, Ciba-Geigy evaluate antisense drug in phase I

April 12, 1996

BR96 produced successfully in milk from transgenic goats

April 12, 1996

Virulizin clinical trials resume in pancreatic cancer

April 12, 1996

Gastrimmune phase I/II trial completed

April 12, 1996

Corixa in-licenses Optivax delivery system for vaccines

April 12, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...